MINI REVIEW article
Front. Med.
Sec. Gene and Cell Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1656570
This article is part of the Research TopicInnovations and Challenges in Gene and Cell Therapy: From Bench to BedsideView all 4 articles
The advantages of NK cell vaccines in solid carcinoma clinical trials:Conducted by various biology Strategy and Technology
Provisionally accepted
- Ansteel Group General Hospital, Anshan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This review systematically discusses the latest clinical progress and challenges of natural killer (NK) cell vaccines in the treatment of solid tumors. By searching databases such as ClinicalTrials.gov and PubMed (2019-2025), we focused on preclinical studies and Phase I/II/III registration trials in the past 2-3 years to dissect the mechanism of action and efficacy data of different vaccine platforms. The study illustrated: Dendritic cell-based vaccine platforms (e.g., ilixadencel), cytokine-based vaccine platforms (e.g., ALT-803), NK receptor agonist antibodies (e.g., AFM24) and mRNA/LNP-based vaccine platforms (e.g., BNT116) It has shown early efficacy in solid tumors such as non-small cell lung cancer, triple-negative breast cancer, and glioblastoma (with partial ORR of 30%-50% and DCR of 80%-100%), and the safety is comparatively manageable (the incidence of grade ≥3 adverse events is less compared to T-cell therapy). However, complex manufacturing procedures, inhibition of the tumor microenvironment, and low targeted delivery efficiency remain the main obstacles to transformation. In the future, combinatorial regimens (e.g., sequential application of PD-1 inhibitors) need to be optimized, an iPSC-NK universal platform developed, and perioperative application scenarios explored. NK vaccines, by reshaping the immune microenvironment, will be an attractive strategy to break the bottlenecks in the treatment of solid tumors.
Keywords: Natural killer (NK) cell-based vaccines, solid tumors, clinical trials, Tumor Microenvironment, cancer immunotherapy
Received: 30 Jun 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Hu, Leng, Li and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qiang Qiao, Ansteel Group General Hospital, Anshan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.